Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Pulmonology

Prognosis and Measuring Progress

At a Glance

IPF prognosis is measured using the GAP Index, which factors in age, gender, and lung function (FVC and DLCO). While historical survival rates were 2 to 5 years, modern antifibrotic medications have significantly improved life expectancy and slowed disease progression.

Understanding your prognosis with Idiopathic Pulmonary Fibrosis (IPF) requires looking at several complex pieces of data. While historical statistics can be frightening, it is important to remember that they often do not reflect the advancements made in modern treatment [1][2].

Understanding the GAP Index

To help predict how the disease might progress, doctors use a staging system called the GAP index [3]. This model uses four simple factors to estimate your risk [4]:

  • G (Gender): Men typically have a slightly higher risk than women [4].
  • A (Age): Risk naturally increases with age [4].
  • P (Physiology): This looks at two key numbers from your lung function tests [5]:
    • FVC (Forced Vital Capacity): How much air you can exhale after a deep breath [6].
    • DLCO (Diffusing Capacity): How well your lungs transfer oxygen into your blood [7].

By adding up points from these categories, your doctor can assign you to GAP Stage I, II, or III [3]. Stage I represents the lowest risk, while Stage III represents a more advanced stage of the disease [8].

Tracking Lung Function

Your care team will monitor your Pulmonary Function Tests (PFTs) closely. A PFT typically involves sitting in a clear booth and breathing forcefully into a tube while wearing a nose clip [9]. They are not just looking at the single numbers, but at the trend over time [10].

  • FVC Decline: It is normal for your FVC to fluctuate by 1-2% day-to-day, so do not panic over minor changes. A true decline of 10% or more in your FVC over a 6-to-12-month period is considered a “clinically significant” sign of disease progression [10][11].
  • DLCO Drops: Because the DLCO measures how your lungs exchange gases, a drop here can sometimes be an even earlier sign of worsening scarring than the FVC [7][12].

Acute Exacerbations (AE-IPF)

An Acute Exacerbation of IPF (AE-IPF) is a sudden, significant worsening of your breathing—usually occurring in less than 30 days [13][14]. It is not a gradual decline, but a rapid flare-up that shows new areas of inflammation or damage on a lung scan [14].

  • Symptoms: Look for a sharp increase in shortness of breath, a new or worsening cough, or a fever [15][16].
  • WARNING: An acute exacerbation is a life-threatening medical emergency. If you experience these sudden symptoms, seek immediate emergency medical care (go to the ER) immediately.
  • Prevention: While some exacerbations happen spontaneously, others can be triggered by respiratory infections or even surgical procedures [17][18]. This is why staying up-to-date on vaccinations and avoiding environmental triggers is a critical part of your care [19].

A Note on Survival

Historically, you may have read that the median survival for IPF is 2 to 5 years [1]. It is vital to know that these numbers are changing. Most of those studies were conducted before the widespread use of antifibrotic medications like nintedanib and pirfenidone [20]. Real-world evidence now shows that these treatments help patients live longer and experience fewer hospitalizations compared to those receiving no treatment [21][22][23]. Your journey is individual, and today’s care options are designed to improve those historical odds.

Common questions in this guide

What is the GAP index for IPF?
The GAP index is a staging system doctors use to predict how idiopathic pulmonary fibrosis might progress. It calculates your risk based on your gender, age, and two key lung function measurements known as FVC and DLCO.
What does a decline in my FVC score mean?
A true decline of 10% or more in your Forced Vital Capacity (FVC) over 6 to 12 months is considered a sign that your IPF is progressing. Minor daily fluctuations of 1 to 2% are normal and usually not a cause for concern.
What is an acute exacerbation of IPF?
An acute exacerbation is a sudden, rapid worsening of breathing symptoms, such as new coughs or increased shortness of breath, often occurring in less than 30 days. This is a life-threatening medical emergency that requires immediate hospital care.
What is the life expectancy for someone with IPF?
While older statistics suggested a median survival of 2 to 5 years, these numbers are outdated. Modern antifibrotic treatments help patients live significantly longer and experience fewer hospitalizations than they did in the past.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current FVC and DLCO scores, what is my GAP score and what stage of IPF does that place me in?
  2. 2.How have my lung function numbers changed over the last six to twelve months, and do you consider that change 'clinically significant'?
  3. 3.Since I am on antifibrotic therapy, how does that change the 'historical' survival estimates for someone in my GAP stage?
  4. 4.What symptoms should I look for that might indicate the start of an acute exacerbation?
  5. 5.Are there specific triggers, like infections or certain procedures, that I should be extra careful to avoid?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.

    Jo HE, Troy LK, Keir G, et al.

    Respirology (Carlton, Vic.) 2017; (22(7)):1436-1458 doi:10.1111/resp.13146.

    PMID: 28845557
  2. 2

    Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis: Joint Consensus of Sociedade Portuguesa de Pneumologia, Sociedade Portuguesa de Radiologia e Medicina Nuclear e Sociedade Portuguesa de Anatomia Patológica.

    Robalo Cordeiro C, Campos P, Carvalho L, et al.

    Revista portuguesa de pneumologia 2016; (22(2)):112-22.

    PMID: 26906287
  3. 3

    The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.

    Harari S, Caminati A, Confalonieri M, et al.

    The clinical respiratory journal 2019; (13(3)):166-173 doi:10.1111/crj.12999.

    PMID: 30675755
  4. 4

    Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg).

    Krauss E, Tello S, Wilhelm J, et al.

    Journal of clinical medicine 2020; (9(11)) doi:10.3390/jcm9113763.

    PMID: 33266405
  5. 5

    Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital.

    Kishaba T, Shimaoka Y, Fukuyama H, et al.

    Journal of thoracic disease 2015; (7(5)):843-9 doi:10.3978/j.issn.2072-1439.2015.04.54.

    PMID: 26101639
  6. 6

    Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry.

    Kim HJ, Weber JM, Neely ML, et al.

    Lung 2025; (203(1)):40 doi:10.1007/s00408-025-00797-4.

    PMID: 40059108
  7. 7

    Mortality-related risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

    Sun X, Lei S, Zhao H, et al.

    Journal of thoracic disease 2024; (16(12)):8338-8349 doi:10.21037/jtd-23-1908.

    PMID: 39831203
  8. 8

    Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality.

    Hyldgaard C, Møller J, Bendstrup E

    European clinical respiratory journal 2020; (7(1)):1807682 doi:10.1080/20018525.2020.1807682.

    PMID: 32944203
  9. 9

    Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.

    Reichmann WM, Yu YF, Macaulay D, et al.

    BMC pulmonary medicine 2015; (15()):167 doi:10.1186/s12890-015-0161-5.

    PMID: 26714746
  10. 10

    Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis.

    Khan FA, Stewart I, Moss S, et al.

    American journal of respiratory and critical care medicine 2022; (205(8)):936-948 doi:10.1164/rccm.202109-2091OC.

    PMID: 35020580
  11. 11

    Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study.

    Veit T, Barnikel M, Crispin A, et al.

    Respiratory research 2020; (21(1)):270 doi:10.1186/s12931-020-01524-8.

    PMID: 33076914
  12. 12

    Insight into the relationship between forced vital capacity and transfer of the lungs for carbon monoxide in patients with idiopathic pulmonary fibrosis.

    Soumagne T, Quétant S, Guillien A, et al.

    Respiratory medicine and research 2023; (84()):101042 doi:10.1016/j.resmer.2023.101042.

    PMID: 37734234
  13. 13

    Current therapies for patients with acute exacerbation of idiopathic pulmonary fibrosis.

    Zhu LL, Dai HP, Wang C

    Chinese medical journal 2020; (133(12)):1470-1472 doi:10.1097/CM9.0000000000000864.

    PMID: 32558705
  14. 14

    Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

    Collard HR, Ryerson CJ, Corte TJ, et al.

    American journal of respiratory and critical care medicine 2016; (194(3)):265-75 doi:10.1164/rccm.201604-0801CI.

    PMID: 27299520
  15. 15

    Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.

    Miyashita K, Kono M, Saito G, et al.

    The clinical respiratory journal 2021; (15(3)):336-344 doi:10.1111/crj.13304.

    PMID: 33197284
  16. 16

    IL-17A contributes to HSV1 infection-induced acute lung injury in a mouse model of pulmonary fibrosis.

    Chen T, Qiu H, Zhao MM, et al.

    Journal of cellular and molecular medicine 2019; (23(2)):908-919 doi:10.1111/jcmm.13992.

    PMID: 30378252
  17. 17

    Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis.

    Kakugawa T, Sakamoto N, Sato S, et al.

    Respiratory research 2016; (17(1)):79 doi:10.1186/s12931-016-0400-1.

    PMID: 27401332
  18. 18

    In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011.

    Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB

    American journal of respiratory and critical care medicine 2016; (193(10)):1161-7 doi:10.1164/rccm.201508-1632OC.

    PMID: 26646481
  19. 19

    Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.

    Chiner-Vives E, Cordovilla-Pérez R, de la Rosa-Carrillo D, et al.

    Archivos de bronconeumologia 2022; (58 Suppl 1()):39-50 doi:10.1016/j.arbres.2022.03.011.

    PMID: 35501222
  20. 20

    A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia.

    Khan MA, Ghamdi BA, Alhamadi M, et al.

    Annals of thoracic medicine 2023; (18(2)):79-85 doi:10.4103/atm.atm_264_22.

    PMID: 37323372
  21. 21

    Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.

    Dempsey TM, Sangaralingham LR, Yao X, et al.

    American journal of respiratory and critical care medicine 2019; (200(2)):168-174 doi:10.1164/rccm.201902-0456OC.

    PMID: 31150266
  22. 22

    Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.

    Behr J, Prasse A, Wirtz H, et al.

    The European respiratory journal 2020; (56(2)) doi:10.1183/13993003.02279-2019.

    PMID: 32381492
  23. 23

    The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.

    Santos G, Fabiano A, Mota PC, et al.

    Pulmonary pharmacology & therapeutics 2023; (83()):102261 doi:10.1016/j.pupt.2023.102261.

    PMID: 37758002

This page explains IPF prognosis and measuring tools for educational purposes only. Always consult your pulmonologist to understand your specific lung function test results and personal survival outlook.

Get notified when new evidence is published on Idiopathic pulmonary fibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.